Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...
Vertex Pharmaceuticals secured a Buy rating from Leerink Partners analyst David Risinger. The firm’s newly approved pain ...
In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated ...
Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...
When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters ...
Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...
The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.
Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...
Last month, the NICE endorsed Casgevy for use in the NHS under a managed access scheme to treat sickle cell disease.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective ...
The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
Mirum gained the drug, which it will sell as Ctexli for adults with cerebrotendinous xanthomatosis, in a 2023 deal with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback